[an error occurred while processing this directive] | [an error occurred while processing this directive]
Prognostic value of pre-treatment prognostic nutrition index in patients with cervical and thoracic upper esophageal squamous cell carcinoma and radiation induced esophagitis
Li Shuguang1, Chen Junqiang2, Li Youmei1, Guo Xuehan1, Deng Wenzhao1, Wang Xiaobin1, Zhu Shuchai1, Shen Wenbin1
1Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 2Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou 350014, China
AbstractObjective To investigate the prognostic value of Onodera's prognostic nutrition index (PNI) before treatment in patients with cervical and upper thoracic esophageal squamous cell carcinoma (CUTESCC) undergoing definitive chemoradiotherapy (dCRT) and its predictive value in the occurrence of ≥ grade 2 radiation esophagitis (RE). Methods The data of 163 CUTESCC patients eligible for inclusion criteria admitted to the Fourth Hospital of Hebei Medical University from January 2012 to December 2017 were retrospectively analyzed. The receiver operating characteristic (ROC) curve was used to calculate the best cut-off value of PNI for predicting the prognosis of patients. The prognosis of patients was analyzed by univariate and Cox multivariate analyses. Logistics binary regression model was adopted to analyze the risk factors of ≥ grade 2 RE in univariate and multivariate analyses. The significant factors in logistic multivariate analysis were used to construct nomogram for predicting ≥ grade 2 RE. Results The optimal cut-off value of PNI was 48.57 [area under the curve (AUC): 0.653, P<0.001]. The median overall survival (OS) and progression-free survival (PFS) were 26.1 and 19.4 months, respectively. The OS (χ2=6.900, P=0.009) and PFS (χ2=9.902, P=0.003) of patients in the PNI ≥ 48.57 group (n=47) were significantly better than those in the PNI < 48.57 group (n=116). Cox multivariate analysis showed that cTNM stage and PNI were the independent predictors of OS (HR=1.513, 95%CI: 1.193-1.920, P=0.001; HR=1.807, 95%CI: 1.164-2.807, P=0.008) and PFS (HR=1.595, 95%CI: 1.247-2.039, P<0.001; HR=2.260, 95%CI: 1.439-3.550, P<0.001). Short-term efficacy was another independent index affecting PFS (HR=2.072, 95%CI: 1.072-4.003, P=0.030). Logistic multivariate analysis showed that the maximum transverse diameter of the lesion (OR=3.026, 95%CI: 1.266-7.229, P=0.013), gross tumor volume (GTV) (OR=3.456, 95%CI: 1.373-8.699, P=0.008), prescription dose (OR=3.124, 95%CI: 1.346-7.246, P=0.009) and PNI (OR=2.072, 95%CI: 1.072-4.003, P=0.030) were the independent factors affecting the occurrence of ≥ grade 2 RE. These four indicators were included in the nomogram model, and ROC curve analysis showed that the model could properly predict the occurrence of ≥ grade 2 RE (AUC=0.686, 95%CI: 0.585-0.787). The calibration curve indicated that the actually observed values were in good agreement with the predicted RE. Decision curve analysis (DCA) demonstrated satisfactory nomogram positive net returns in most threshold probabilities. Conclusions PNI before treatment is an independent prognostic factor for patients with CUTESCC who received definitive chemoradiotherapy. The maximum transverse diameter of the lesion, GTV, prescription dose and PNI are the risk factors for ≥ grade 2 RE in this cohort. Establishing a prediction model including these factors has greater predictive value.
Li Shuguang,Chen Junqiang,Li Youmei et al. Prognostic value of pre-treatment prognostic nutrition index in patients with cervical and thoracic upper esophageal squamous cell carcinoma and radiation induced esophagitis[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 689-696.
Li Shuguang,Chen Junqiang,Li Youmei et al. Prognostic value of pre-treatment prognostic nutrition index in patients with cervical and thoracic upper esophageal squamous cell carcinoma and radiation induced esophagitis[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 689-696.
[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660. [2] He SM, Xu J, Liu XJ, et al.Advances and challenges in the treatment of esophageal cancer[J]. Acta Pharm Sin B, 2021,11(11):3379-3392. DOI: 10.1016/j.apsb.2021.03.008. [3] Wang HW, Chu PY, Kuo KT, et al.A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction[J]. J Surg Oncol, 2006,93(6):468-476. DOI: 10.1002/jso.20472. [4] Olsen TA, Zhuang TZ, Caulfield S, et al.Advances in knowledge and management of immune-related adverse events in cancer immunotherapy[J]. Front Endocrinol (Lausanne), 2022,13:779915. DOI: 10.3389/fendo.2022.779915. [5] Favareto SL, Sousa CF, Pinto PJ, et al.Clinical prognostic factors for patients with esophageal cancer treated with definitive chemoradiotherapy[J]. Cureus,2021,13(10):e18894. DOI:10.7759/cureus.18894.eCollection2021Oct. [6] Rose J, Rodrigues G, Yaremko B, et al.Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy[J]. Radiother Oncol, 2009,91(3):282-287. DOI: 10.1016/j.radonc.2008.09.010. [7] Kang JJ, Yang GS, Wang DS, et al.The clinical application value of the prognostic nutritional index for the overall survival prognosis of patients with esophageal cancer: a robust real-world observational study in China[J]. Comput Math Methods Med, 2022,2022:3889588. DOI: 10.1155/2022/3889588. [8] Tanaka S, Uchino J, Yokoi T, et al.Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer[J]. Diagnostics (Basel), 2022,12(2):423. DOI: 10.3390/diagnostics12020423. [9] Xie HL, Wei LS, Yuan GH, et al.Prognostic value of prognostic nutritional index in patients with colorectal cancer undergoing surgical treatment[J]. Front Nutr, 2022,9:794489. DOI: 10.3389/fnut.2022.794489. [10] 白文文, 周志国, 甄婵军, 等. 159例颈及胸上段食管癌调强放疗长期疗效[J]. 中华放射医学与防护杂志,2016,36(1):28-34. DOI: 10.3760/cma.j.issn.0254-5098.2016.01.005. Bai W, Zhou ZG, Zhen C, et al. Long-term effificacy of 159 cases of cervical and upper esophageal carcinoma treated with intensity-modulated radiotherapy[J]. Chin J Radiol Med Prot, 2016,36(1):28-34. DOI: 10.3760/cma.j.issn. 0254-5098.2016.01.005. [11] Zhang JQ, Zhang WC, Zhang BZ, et al.Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma[J]. Cancer Manag Res, 2019,11:8285-8294. DOI: 10.2147/CMAR.S203575. [12] Esmati E, Maddah Safaei A, Ghalehtaki R, et al.Outcomes of definitive chemoradiotherapy for cervical and upper thoracic esophageal cancers: a single-institution experience of a rare cancer[J]. J Gastrointest Cancer, 2019,50(3):380-385. DOI: 10.1007/s12029-018-0081-8. [13] Du XX, Yu R, Wang ZF, et al.Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy[J]. Bosn J Basic Med Sci, 2019,19(2):186-194. DOI: 10.17305/bjbms.2019.3873. [14] Li HX, Liu J, Cheng Y, et al.Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study[J]. Dis Esophagus, 2018,31(5). DOI: 10.1093/dote/dox144. [15] Cools-Lartigue J, Markar S, Mueller C, et al.An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma[J]. Ann Surg, 2022,276(5):799-805. DOI: 10.1097/SLA.0000000000005619. [16] de Gouw D, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis[J]. J Thorac Oncol, 2019,14(7):1156-1171. DOI: 10.1016/j.jtho.2019.04.004. [17] Huang RH, Guo H, Chen JZ, et al.Intratreatment tumor volume change during definitive chemoradiotherapy is predictive for treatment outcome of patients with esophageal carcinoma[J]. Cancer Manag Res, 2020,12:7331-7339. DOI: 10.2147/CMAR.S246500. [18] Li DJ, Zhang Q, Yang Y, et al.Significance of intratreatment tumor volume change during chemoradiotherapy for potentially resectable thoracic esophageal squamous cell carcinoma[J]. Am J Transl Res, 2022,14(7):4776-4785. [19] Chen XH, Yu YL, Wu HS, et al.A novel model combining tumor length, tumor thickness, TNM_stage, nutritional index, and inflammatory index might be superior to the 8th TNM staging criteria in predicting the prognosis of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy[J]. Front Oncol, 2022,12:896788. DOI: 10.3389/fonc.2022.896788. [20] Dai YQ, Fu XB, Li TT, et al.Long-term impact of prognostic nutritional index in cervical esophageal squamous cell carcinoma patients undergoing definitive radiotherapy[J]. Ann Transl Med, 2019,7(8):175. DOI: 10.21037/atm.2019.03.60. [21] Kang JJ, Yang GS, Wang DS, et al.The clinical application value of the prognostic nutritional index for the overall survival prognosis of patients with esophageal cancer: a robust real-world observational study in China[J]. Comput Math Methods Med, 2022,2022:3889588. DOI: 10.1155/2022/3889588. [22] Onodera T, Goseki N, Kosaki G.[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients][J]. Nihon Geka Gakkai Zasshi, 1984,85(9):1001-1005. [23] Tang C, Liao ZX, Zhuang Y, et al.Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer[J]. Radiother Oncol, 2014,110(3):493-498. DOI: 10.1016/j.radonc.2014.01.009. [24] Dong J, Zhang WC, Zhang T, et al.Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy[J]. Ann Transl Med, 2020,8(18):1148. DOI: 10.21037/atm-20-4078. [25] Yu YL, Zheng HY, Liu LY, et al.Predicting severe radiation esophagitis in patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy: construction and validation of a model based in the clinical and dosimetric parameters as well as inflammatory indexes[J]. Front Oncol, 2021,11:687035. DOI: 10.3389/fonc.2021.687035.
2023, Vol. 32 
